Literature DB >> 29571807

Cumulative effective dose and cancer risk for pediatric population in repetitive full spine follow-up imaging: How micro dose is the EOS microdose protocol?

Martin Law1, Wang-Kei Ma2, Damian Lau2, Kenneth Cheung2, Janice Ip2, Lawrance Yip2, Wendy Lam2.   

Abstract

OBJECTIVE: To evaluate and to obtain analytic formulation for the calculation of the effective dose and associated cancer risk using the EOS microdose protocol for scoliotic pediatric patients undergoing full spine imaging at different age of exposure; to demonstrate the microdose protocol capable of delivering lesser radiation dose and hence of further reducing cancer risk induction when compared with the EOS low dose protocol; to obtain cumulative effective dose and cancer risk for both genders scoliotic pediatrics of US and Hong Kong population using the microdose protocol.
METHODS: Organ absorbed doses of full spine exposed scoliotic pediatric patients have been simulated with the use of EOS microdose protocol imaging parameters input to the Monte Carlo software PCXMC. Gender and age specific effective dose has been calculated with the simulated organ absorbed dose using the ICRP-103 approach. The associated radiation induced cancer risk, expressed as lifetime attributable risk (LAR), has been estimated according to the method introduced in the Biological Effects of Ionizing Radiation VII report. Values of LAR have been estimated for scoliotic patients exposed repetitively during their follow up period at different age for US and Hong Kong population.
RESULTS: The effective doses of full spine imaging with simultaneous posteroanterior and lateral projection for patients exposed at the age between 5 and 18 years using the EOS microdose protocol have been calculated within the range of 2.54-14.75 μSv. The corresponding LAR for US and Hong Kong population was ranged between 0.04 × 10-6 and 0.84 × 10-6. Cumulative effective dose and cancer risk during follow-up period can be estimated using the results and are of information to patients and their parents.
CONCLUSION: With the use of computer simulation and analytic formulation, we obtained the cumulative effective dose and cancer risk at any age of exposure for pediatric patients of US and Hong Kong population undergoing repetitive microdose protocol full spine imaging. Girls would be at a statistically significant higher cumulative cancer risk than boys undergoing the same microdose full spine imaging protocol and the same follow-up schedule.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cumulative cancer risk; Cumulative effective dose; EOS microdose protocol; Full spine imaging for scoliosis follow-up

Mesh:

Year:  2018        PMID: 29571807     DOI: 10.1016/j.ejrad.2018.02.015

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  4 in total

1.  Data on the estimating the risk of cancer due to some common radiographs in Tehran city.

Authors:  Mohammad Mirdoraghi; Amin Banaei; Jafar Fatahi Asl
Journal:  Data Brief       Date:  2018-09-06

2.  Visual Evaluation of Image Quality of a Low Dose 2D/3D Slot Scanner Imaging System Compared to Two Conventional Digital Radiography X-ray Imaging Systems.

Authors:  Ahmed Jibril Abdi; Bo Mussmann; Alistair Mackenzie; Oke Gerke; Gitte Maria Jørgensen; Thor Eriksen Bechsgaard; Janni Jensen; Lone Brunshøj Olsen; Poul Erik Andersen
Journal:  Diagnostics (Basel)       Date:  2021-10-19

3.  Decreased Vertical Trunk Inclination Angle and Pelvic Inclination as the Result of Mid-High-Heeled Footwear on Static Posture Parameters in Asymptomatic Young Adult Women.

Authors:  Jakub Michoński; Marcin Witkowski; Bożena Glinkowska; Robert Sitnik; Wojciech Glinkowski
Journal:  Int J Environ Res Public Health       Date:  2019-11-18       Impact factor: 3.390

Review 4.  Benefits of Low-Dose CT Scan of Head for Patients With Intracranial Hemorrhage.

Authors:  Dan Wu; Gang Wang; Bingyang Bian; Zhuohang Liu; Dan Li
Journal:  Dose Response       Date:  2020-03-06       Impact factor: 2.658

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.